Canada markets open in 3 hours 9 minutes
  • S&P/TSX

    20,215.12
    +50.73 (+0.25%)
     
  • S&P 500

    4,266.49
    +24.65 (+0.58%)
     
  • DOW

    34,196.82
    +322.58 (+0.95%)
     
  • CAD/USD

    0.8124
    +0.0009 (+0.11%)
     
  • CRUDE OIL

    72.86
    -0.44 (-0.60%)
     
  • BTC-CAD

    41,625.75
    +355.04 (+0.86%)
     
  • CMC Crypto 200

    808.97
    +22.36 (+2.84%)
     
  • GOLD FUTURES

    1,783.00
    +6.30 (+0.35%)
     
  • RUSSELL 2000

    2,333.62
    +30.15 (+1.31%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,380.25
    +26.00 (+0.18%)
     
  • VOLATILITY

    15.99
    -0.33 (-2.02%)
     
  • FTSE

    7,113.39
    +3.42 (+0.05%)
     
  • NIKKEI 225

    29,066.18
    +190.95 (+0.66%)
     
  • CAD/EUR

    0.6800
    +0.0002 (+0.03%)
     

Myovant Sciences: Fiscal Q4 Earnings Snapshot

·1 min read

LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Tuesday reported a loss of $81.4 million in its fiscal fourth quarter.

On a per-share basis, the London-based company said it had a loss of 89 cents.

The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 99 cents per share.

The biopharmaceutical company posted revenue of $24.6 million in the period.

For the year, the company reported that its loss narrowed to $255.1 million, or $2.83 per share. Revenue was reported as $59.3 million.

Myovant Sciences shares have fallen 34% since the beginning of the year. The stock has risen 45% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYOV at https://www.zacks.com/ap/MYOV

The Associated Press

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting